Blood Pressure Supplements After 65: What Ranks First?

Tart cherry juice ranked first and inorganic nitrate ranked second for lowering systolic blood pressure in adults 65 and older. That sounds like a shopping list. It is not. In the only network meta-analysis built specifically for this age group, neither supplement beat placebo at statistical significance, and the placebo group showed a numerically larger average reduction than either top-ranked treatment.

The ranking is still useful, provided you read it as a map of uncertainty rather than a prescription. It points toward nitrate-rich beetroot products and tart cherry as the most plausible candidates among the supplements tested. It does not show that either reliably lowers blood pressure in an individual older adult.

The over-65 ranking, and its catch

A 2024 network meta-analysis by Kujawska et al. began with 144 candidate randomized trials and retained 12 after applying criteria that required placebo control, an average age of at least 65 years in both study arms, and usable before-and-after blood-pressure data. The exclusions were substantial: 83% of candidate trials did not qualify.

The final network compared DHA/EPA omega-3 fatty acids, inorganic nitrates, tart cherry juice, resveratrol, vitamins D, E, and K2, and protein supplements. Tart cherry juice had the highest P-score for systolic blood-pressure reduction, followed by inorganic nitrate.

A P-score ranks point estimates across a network. It does not turn an uncertain estimate into a proven effect. Every active-versus-placebo and active-versus-active comparison had a 95% confidence interval that crossed zero. In other words, none produced a statistically significant difference. The analysis also found no statistically significant moderation by treatment duration or baseline blood pressure, but a 12-trial network has little power to detect such patterns.

The awkward detail matters most: the pooled placebo response was numerically larger than the average reductions for the two leading supplements. Small samples, unequal starting blood pressure, regression to the mean, and random error could all produce that result. The study cannot distinguish among them. It also cannot establish that placebo lowers blood pressure better than tart cherry or nitrate; the comparisons were not statistically significant.

Why nitrate still deserves the closest look

Outside the narrow over-65 network, inorganic nitrate has a stronger evidence base than the ranking alone suggests. A 2025 GRADE-assessed systematic review and dose-response meta-analysis of randomized trials found statistically significant, dose-dependent reductions in systolic and diastolic blood pressure with dietary or plasma nitrate. It also reported improvements in pulse-wave velocity and flow-mediated dilation, measures of arterial stiffness and endothelial function.

The biology is plausible. Oral bacteria convert dietary nitrate to nitrite, which can then contribute to nitric oxide production in the stomach and peripheral tissues. Nitric oxide relaxes vascular smooth muscle. This nitrate-to-nitrite route does not depend entirely on endothelial nitric oxide synthase, whose activity tends to decline with age.

But broader adult evidence does not settle the question for older adults. A 2022 systematic review of inorganic nitrate in older adults found heterogeneous, contested blood-pressure results. That disagreement fits the null pairwise findings in the over-65 network better than it fits a confident claim that beetroot juice works for everyone past retirement age.

Baseline blood pressure may explain part of the inconsistency. A 2024 beetroot-juice meta-analysis found significant systolic reductions in people with grade 1–2 hypertension, defined there as baseline blood pressure of at least 140/90 mmHg. It did not find a significant effect in normotensive or milder groups. The implication is practical: someone with normal or high-normal readings should not expect the same response as someone with established hypertension.

There is also direct vascular evidence in a clinically distinct older population. In a 2025 randomized trial in older people with Alzheimer's disease, nitrate-rich beetroot juice improved vascular responsiveness. That is a vascular endpoint, not proof of lower long-term blood pressure or fewer cardiovascular events. Still, it supports the idea that dietary nitrate can affect blood-vessel function when nitric-oxide availability is impaired.

Tart cherry has a plausible pathway, not a confirmed BP effect

Tart cherry juice led the systolic ranking, but it lacks a standalone age-specific meta-analysis that confirms a blood-pressure effect. Its case rests on the fragile network ranking and on evidence from related polyphenol sources.

A double-blind randomized trial of wild blueberry polyphenols in healthy older adults found improved flow-mediated dilation and vascular function. Blueberries are not tart cherries, and improved flow-mediated dilation is not the same outcome as reduced blood pressure. The trial does, however, support biological plausibility for anthocyanin-rich polyphenols in aging blood vessels.

That makes tart cherry a reasonable low-risk adjunct for people who enjoy it and can fit it into their diet. It does not make it a blood-pressure treatment with independent confirmation in adults over 65.

Why rankings cannot predict your response

Even nitrate's average effect may conceal sharply different individual responses. A 2025 double-blind, placebo-controlled replicate crossover trial found reproducible differences in blood-pressure response to dietary nitrate, including non-responders. Repeating exposures helps separate true biological variation from one-off measurement noise. A population average can therefore mix people who respond with people who do not.

Sex may matter as well, although the available evidence does not answer the question in older women. A 2023 acute beetroot-juice study found significant blood-pressure reductions in young Black and White men but no significant effect in women from the same cohort. That study involved young adults and an acute exposure, so it cannot be projected directly onto postmenopausal women. It does show why aggregate estimates without sex-stratified results deserve restraint.

The 2024 network meta-analysis had other limits: included studies spanned 2003 to 2022, risk-of-bias assessments ranged from low risk to high risk, and the network was too small to assess publication bias reliably. Its rankings are the best age-specific comparison available, but they remain preliminary.

What about the rest of the supplement shelf?

Resveratrol, vitamin D, vitamin E, vitamin K2, DHA/EPA, and protein ranked below tart cherry and inorganic nitrate in the network. None had a statistically significant effect versus placebo in that analysis. They may have other uses in specific circumstances, but the available over-65 evidence does not support choosing them specifically to lower blood pressure.

Nicotinamide riboside is an emerging exception only in the sense that it was not part of the ranking. A 2025 pilot randomized trial tested 1,000 mg per day of nicotinamide riboside plus supervised walking three days per week for six weeks in 54 sedentary adults aged 55 and older with mean daytime systolic blood pressure of at least 130 mmHg. The combination showed greater blood-pressure effects than exercise alone, but the pilot design and small sample do not justify ranking it against established candidates.

A practical verdict

For an adult over 65 with confirmed systolic hypertension, nitrate-rich beetroot juice or a concentrated inorganic nitrate product has the strongest rationale among the supplements in this comparison. That conclusion rests on broader randomized evidence, a plausible mechanism, and a second-place ranking in the age-specific network—not on a statistically significant win within that network.

Tart cherry juice is a plausible adjunct, but its blood-pressure claim is weaker. For either option, measure blood pressure consistently for four to six weeks rather than trusting a single reading or a label. Use the same validated cuff, similar timing, and multiple readings per session. A supplement that does nothing for your readings is still doing nothing, even if its P-score had excellent manners.

Do not use supplements to delay indicated hypertension treatment. No supplement in the over-65 network showed a statistically significant advantage over placebo, and none has replaced standard antihypertensive care.